Pharmacy Times

AUGUST 2, 2025

These technologies prevent the risk of both hypo- and hyperglycemic episodes, facilitating safer fasting. The guidance is updated every 5 years, with the most recent update published in May 2025. Monitoring technology is valuable to assess glycemic control and enable timely interventions in T1D patients.

HIV Treatment and Prevention Agents

Pharmacy Times

JULY 1, 2025

SHOW MORE Pharmacists can help oversee the treatment process to ensure patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are adhering to tafamidis. Ongoing research explores tafamidis' long-term efficacy, potential in other heart failure forms, and combination therapies for enhanced outcomes.

HIV Treatment and Prevention Agents

Pharmacy Times

AUGUST 7, 2025

Pharmacists are essential in managing OIC, advising on treatment, monitoring effectiveness, and identifying contraindications and potential complications. Pharmacological support often starts with OTC agents, like water-holding laxatives (e.g., polyethylene glycol and lactulose) and stimulant laxatives (e.g., bisacodyl and senna).

HIV Treatment and Prevention Agents

Pharmacy Times

JUNE 16, 2025

Although the use of colony-stimulating factors (CSFs) is well-established in mitigating severe FN, existing literature suggests there is only an approximate 3% difference in FN rates between various CSF agents. Utilizing colony-stimulating factors (CSFs) decreases the incidence of severe FN.

HIV Treatment and Prevention Agents

Pharmacy Times

JUNE 10, 2025

3 Although meloxicam injection delivers a non-opioid alternative for pain control, it is not recommended as a first-line agent when rapid onset of analgesia is needed due to its delayed onset. 2 REFERENCES 1. Meloxicam: Selective COX-2 inhibition in clinical practice. Seminars in Arthritis and Rheumatism. December 21, 2004. Subscribe Now!

FDA

Pharmacy Times

JUNE 23, 2025

The presentation emphasized early intervention and personalized treatment plans in managing type 2 diabetes, shifting from "treating to failure" to "treating to target." It is not indicated for type 1 diabetes and carries a boxed warning for thyroid C-cell tumors, with unknown risk in humans.

HIV Treatment and Prevention Agents

Pharmacy Times

JULY 21, 2025

Cardiovascular disease risks in HIV patients have evolved with ART, requiring preventive measures like statins and cardiovascular risk scores for effective management. Healthy aging in HIV patients involves addressing accelerated aging, multimorbidity, and geriatric syndromes, emphasizing functional ability and quality of life.

HIV Treatment and Prevention Agents

Drug Topics

JULY 30, 2025

Prescription cascades refer to a medication being prescribed to prevent or treat an adverse drug reaction to another medication. Further, it would be potentially inappropriate if there are more suitable treatment alternatives available, such as switching the drug causing the adverse drug reaction.

HIV Treatment and Prevention Agents

Pharmacy Times

JULY 8, 2025

Further research is needed on the clinical impact, treatment longevity, and cost implications of biosimilar use in pediatric IBD. 2 Tumor necrosis factor alpha inhibitors (anti-TNFs) have become both first- and second-line therapies for the treatment of pediatric patients with Crohn disease and ulcerative colitis.

HIV Treatment and Prevention Agents

Pharmacy Times

JULY 17, 2025

Understanding and addressing barriers to medication adherence are crucial for effective treatment of psychiatric disorders and improving patient outcomes. Long-acting injectable antipsychotics may improve adherence in homeless populations, but transportation and clinic visit logistics must be considered.

HIV Treatment and Prevention Agents

Pharmacy Times

AUGUST 7, 2025

The FDA's fast track designation highlights birelentinib's potential to meet unmet needs in CLL/SLL treatment. A cornerstone of treatment for these patients is BTK and BCL-2 inhibitors, but many patients progress or relapse on these therapies.

HIV Treatment and Prevention Agents

Pharmaceutical Technology

JULY 2, 2025

How will RFK Jr’s American dream for vaccines play out? Gilead’s recently approved drug for HIV prevention, Yeztugo (lenacapavir), has the potential to transform the pre-exposure prophylaxis (PrEP) sector in the US, according to market analysts. Reports LOA and PTSR Model - GS-1720 in Human Immunodeficiency Virus (HIV).

HIV Treatment and Prevention Agents

Pharmacy Times

JULY 3, 2025

She emphasizes that treatment options are mostly supportive, making prevention through good hygiene and vaccination essential. Pharmacists play a crucial role in educating high-risk individuals about RSV risks and encouraging vaccination to reduce severe illness.

HIV Treatment and Prevention Agents

Pharmaceutical Technology

JUNE 11, 2025

The US Food and Drug Administration (FDA) has placed a clinical hold on several of Gilead’s trials evaluating two HIV treatment candidates, though the rest of the drugmaker’s diverse pipeline remains unaffected. Gilead is considered the leading big pharma in HIV treatments. Shares in Nasdaq-listed Gilead opened 0.3%

HIV Treatment and Prevention Agents

Pharmacy Times

JULY 15, 2025

Upon sensing dsRNA, the cell effectively halts protein synthesis, thereby preventing the virus from manufacturing the essential proteins required for its own reproduction. This innovative approach allowed for the high-throughput screening of many compounds, specifically 370,830, to discover potential therapeutic agents.

Compounding

Pharmacy Friday Pearls

MARCH 4, 2022

18 years Administration Oral Oral Oral PK/PD MOA: Nirmatrelvir – inhibitor of the SARS-CoV-2 main protease Prevents viral replicationRitonavir is a CYP3A inhibitor included to increase nirmatrelvir plasma levelsRitonavir alone has NO activity against SARS-CoV-2 Time to peak: Nirmatrelvir: 3 hrs & Ritonavir: 3.98 Introduction.

HIV Treatment and Prevention Agents

The Checkup by Singlecare

FEBRUARY 6, 2023

Pneumonia is often mild to moderate, requiring only outpatient treatment. Risk factors of pneumonia are age older than 65, chronic obstructive pulmonary disorder ( COPD ), HIV infection , weakened immune system and smoking. Pneumonia usually requires evaluation and treatment. Treatment depends on the cause.

HIV Treatment and Prevention Agents